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Abstract
Currently two vaccines, trivalent inactivated influenza vaccine (TIV) and live attenuated influenza vaccine (LAIV), are licensed
in the USA. Despite previous studies on immune responses induced by these two vaccines, a comparative study of the
influence of prior influenza vaccination on serum antibody and B-cell responses to new LAIV or TIV vaccination has not been
reported. During the 2005/6 influenza season, we quantified the serum antibody and B-cell responses to LAIV or TIV in
adults with differing influenza vaccination histories in the prior year: LAIV, TIV, or neither. Blood samples were collected on
days 0, 7–9 and 21–35 after immunization and used for serum HAI assay and B-cell assays. Total and influenza-specific
circulating IgG and IgA antibody secreting cells (ASC) in PBMC were detected by direct ELISPOT assay. Memory B cells were
also tested by ELISPOT after polyclonal stimulation of PBMC in vitro. Serum antibody, effector, and memory B-cell responses
were greater in TIV recipients than LAIV recipients. Prior year TIV recipients had significantly higher baseline HAI titers, but
lower HAI response after vaccination with either TIV or LAIV, and lower IgA ASC response after vaccination with TIV than
prior year LAIV or no vaccination recipients. Lower levels of baseline HAI titer were associated with a greater fold-increase of
HAI titer and ASC number after vaccination, which also differed by type of vaccine. Our findings suggest that the type of
vaccine received in the prior year affects the serum antibody and the B-cell responses to subsequent vaccination. In
particular, prior year TIV vaccination is associated with sustained higher HAI titer one year later but lower antibody response
to new LAIV or TIV vaccination, and a lower effector B-cell response to new TIV but not LAIV vaccination.
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Introduction
Influenza virus can cause severe respiratory illness in young
children and adults, which can lead to death, especially in the
elderly over 65 years old [1]. On average 5–20% of the population
is infected with influenza virus in the United States every year
[2,3], resulting in a considerable economic burden [4]. To prevent
seasonal influenza, the Centers for Disease Control and Prevention
recommends annual influenza vaccination. Humoral antibody to
the influenza hemagglutinin (HA), which is induced by natural
infection or vaccination, has an important role in protection. Most
adults and older children have pre-existing levels of antibody
because of prior infection or vaccination [5,6]. However, antigenic
drift of influenza virus, which is caused by an accumulation of
point mutations in the HA and neuraminidase (NA) genes, occurs
both in influenza A and B viruses [7–9]. An individual who was
infected by or previously vaccinated against influenza viruses
circulating in prior years may still be susceptible to a new virus
strain. Therefore, influenza vaccines are reformulated each year
based on the results of international surveillance that predict the
virus strains that will circulate in a subsequent year.
There are two types of vaccines available in the US: inactivated
trivalent influenza vaccine (TIV) and live attenuated influenza
vaccine (LAIV). Both vaccines contain two influenza A viruses
(H1N1 and H3N2) and one influenza B virus. Inactivated
influenza vaccine has been used since 1945 and the accumulated
studies confirm that the hemagglutination inhibition (HAI)
antibody response after vaccination correlates with protection
against subsequent influenza infection [10–12]. Therefore, serum
antibody responses are used as a surrogate marker for the efficacy
of TIV for the purpose of annual re-licensing. LAIV was licensed
in the US in 2003. Intranasal administration of LAIV induced a
robust serum and mucosal antibody response in young, non-
immune children [13,14]. However, the magnitude of influenza-
specific antibody response in the serum of older children and
adults is generally substantially lower compared to what is seen
following immunization with TIV [5,15,16]. Despite the lower
serum response observed in the circulation following LAIV
immunization in healthy adults and older children, vaccine
efficacy appears to be at least comparable to TIV [17–19]. TIV
is approved for use in people older than 6 months, including
healthy people and people with chronic medical conditions [20].
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are not pregnant and are without a history of asthma or recurrent
wheezing [20]. Therefore, most healthy adults under 49 years of
age and healthy children older than 2 years of age can choose
between these two vaccines in the US.
Although annual vaccination is recommended for all ages, the
efficacy of repeated vaccination with TIV has been debated for
many years [21–23]. The Hoskins study concluded that repeated
vaccination was not protective for the long term, while more
recent studies have generally, but not universally, concluded that
repeated vaccination was effective over the long term [22,24,25].
Many factors, including type of vaccine (live or inactivated), match
of antigenicity between vaccine and circulating influenza strains,
age, and study design, influenced the evaluation of vaccine efficacy
[6,23,26]. While several studies have shown that TIV vaccination
resulted in higher serum antibody titers after one year compared
to unvaccinated controls [21,27–30], other immune markers, such
as memory B-cells and long-lived plasma cells have not been
thoroughly investigated. In our previous study during the 2004–
2005 influenza season, we observed that the titer of neutralizing
antibody to H3N2 in serum was significantly higher in adult
subjects who received TIV during the previous 2003–2004 season
compared to those who had LAIV [5]. On the other hand, a year
after vaccination, the levels of influenza-specific circulating
memory B cells were similar between LAIV and TIV recipients
[5]. However, the influences of prior year vaccination on the
antibody and B-cell responses to re-vaccination have not been
analyzed in detail, especially after LAIV vaccination. To address
this issue in a new study carried out during the 2005–2006
influenza season, we investigated the serum antibody response,
effector B-cell (antibody secreting cell, ASC) response, and
memory B-cell response in adult subjects who were not or were
vaccinated with either LAIV or TIV in the prior year, and
received a new dose of the influenza vaccine (either TIV or LAIV).
Materials and Methods
Human subjects and vaccination protocols
Sixty one healthy adults (age range 22–49 years) were enrolled
in this study between September and early December 2005. These
subjects were randomized at a 1:1 ratio to receive one dose of
either TIV (FluzoneH, Aventis-Pasteur) or LAIV (FluMistH,
MedImmune). In the LAIV group (n=31), 14 subjects did not
receive influenza vaccine in the prior year, 4 received LAIV, and
13 received TIV. In the TIV group (n=30), 14 subjects did not
receive influenza vaccine in the prior year, 9 received LAIV, and 7
received TIV. None of the subjects had chronic cardiovascular or
pulmonary disorders, a history of asthma or reactive airway
disease, autoimmune disease, immunosuppression, immunodefi-
ciency or impaired immunologic functions, allergies to any
component of the vaccine including thimerosal, or allergy to eggs
or egg products. The study protocol was approved by the
institutional review board at Stanford University. Written
informed consent was obtained from all participants.
Three blood samples were obtained from each subject: on day 0
prior to vaccination, and day 7 (range 7–9) and 30 (range 21–35)
after vaccination. The 2005–2006 TIV and LAIV vaccines both
contained the A/New Caledonia/20/99 (H1N1) and B/Jiangsu/
10/2003 (B) strains. The third strain was A/California/7/2004
(H3N2) in LAIV and A/NewYork/55/2004 (H3N2, an A/
California/7/2004-like strain) in TIV. The prior year 2004–2005
TIV and LAIV vaccines both contained A/New Caledonia/20/99
(H1N1)andA/Wyoming/03/2003 (H3N2)strains.The third strain
was B/Jiangsu/10/2003 in TIV and B/Jilin/20/2003 in LAIV.
2-color ELISPOT assay for antibody secreting cells (ASC)
PBMC were isolated from heparinized whole blood by ficoll
gradient centrifugation and resuspended in RPMI1640 (Gibco,
Grand Island, NY) containing 10% fetal calf serum (FCS,
Hyclone, South Logan, UT). Total and influenza-specific IgA
and IgG ASC were detected simultaneously as previously
described [5]. In brief, 96-well plates (Immobilon P membrane,
MAIPN4510, Milipore, Billerica, MA) were coated with TIV at a
total concentration of 9 mg/ml in PBS to detect influenza-specific
ASC, or coated with affinity purified goat anti-human IgA+Ig-
G+IgM (H+L) (KPL, Gaithersburg, MD) in PBS to detect total
ASC. The influenza coating antigen was a 1:1 mixture of TIV
2002–2003, which had the same components as TIV 2003–2004,
and TIV 2005–2006. Wells coated with PBS served as negative
controls. Plates were incubated overnight at 4uC and then blocked
for 2 hr at 37uC with RPMI 1640 containing 10% FCS, 100
units/ml of penicillin G and 100 mg/ml of streptomycin (Gibco),
referred to as complete medium. Freshly isolated PBMC or
cultured PBMC (see below) were resuspended in complete
medium containing peroxidase conjugated goat anti-human IgA
antibody (Sigma, St. Louis, MO) and phosphatase conjugated goat
anti-human IgG (H+L) antibody (KPL), dispensed into ELISPOT
plates and incubated for 4 hrs or longer at 37uCi naC O 2
incubator. Plates were washed with PBS and developed first with
an AEC substrate kit for peroxidase (Vector, Burlingame, CA) and
subsequently with a Blue alkaline phosphatase substrate kit
(Vector). IgA ASC was visualized as red spots and IgG ASC as
blue spots in the same wells. The quantity of ASC per well was
determined by counting the spots with an ELISPOT plate reader
(CTL-ImmunoSpotH S5 Macro Analyzer, with the software
ImmunoSpot version 3.2, Cellular Technology Ltd. OH).
Nonspecific spots detected in the negative control (PBS) wells
were subtracted from the counts of influenza-specific and total
ASC.
Memory B-cell assay
To detect memory B cells, PBMC were stimulated to induce
differentiation of memory B-cells into ASC, as described by Crotty
et al. [31]. PBMC were distributed into 24-well plates (Costar,
Corning, NY) at 5610
5 cells/well in complete medium with
55 mM of 2-mercaptoethanol and a mixture of polyclonal
mitogens: 1/100,000 dilution of pokeweed mitogen extract
(PWM, kindly provided by Dr. R. Ahmed, Emory University,
Atlanta, GA), 6 mg/ml of CpG olygonucletide ODN-2006
(Invivogen, San Diego, CA), and 1/10,000 dilution of fixed
Staphylococcus aureus Cowan (SAC) (Sigma). Duplicate wells were
cultured for each subject. Cells cultured in complete medium with
2-mercaptoethanol but without CpG, SAC, and PWM served as
negative controls. Cells were cultured for 5–6 days at 37uCi na
CO2 incubator. The cultured cells were washed twice with
complete medium and transferred into coated ELISPOT plates as
described above. To adjust for the background of the ELISPOT
assay, we subtracted the number of nonspecific spots (PBS control)
from the count of influenza-specific or total ASC. We then
estimated the number of ASC differentiated from memory B cells
by subtracting the number of influenza-specific or total ASC in
unstimulated samples (negative controls) from those in stimulated
samples. Data are presented as the percentage of influenza–
specific ASC per total ASC per culture well [31].
Serum hemagglutination inhibition assays
Serum samples were pretreated with receptor-destroying
enzyme (RDE) (Denka Seiken, Tokyo) overnight at 37uC and
subsequently heated at 56uC for 45 min. Hemagglutination
B-Cell Response
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In brief, serially diluted 25 ml aliquots of serum samples in PBS
were mixed with 25 ml aliquots of virus, corresponding to four HA
units, in V-bottom 96-well plates (Nunc, Rochester, NY) and
incubated for 30 min at room temperature. At the end of the
incubation, 50 ml of 0.5% chicken (for influenza H1) or turkey (for
influenza H3 viruses) red blood cells were added and incubated for
a minimum of 30 min. The serum HAI antibody titer of a given
sample was defined as the reciprocal of the last serum dilution with
no hemagglutination. A titer of 2 was assigned to all samples in
which the first dilution (1:4) was hemagglutination-negative.
Statistical analysis
Throughout, data are summarized by group as the mean61
standard error when skewness of data is less than 1. For skewness
.1, data are log transformed and summarized by group as the
geometric mean (and 95% confidence interval). Two-sample
comparisons employed unpaired t-tests for normally distributed
data (with Welch’s correction if sample variances were sufficiently
different). We employed The Wilcoxon signed rank test for two
related samples (the data before and after vaccination). Correlation
was assessed using Spearman’s coefficient to include detection of
any monotonic association.
We employed generalized estimating equations (GEE) for
regression analysis of longitudinal data [33]. GEE analysis
assumed the variance is a quadratic function of the mean under
a logarithm link function. The GEE regression model assumed
that ASC response is a function of vaccine type, linear and
quadratic terms for days after vaccination, year, and interactions
of vaccine type with linear and quadratic terms for days after
vaccination. Because the sampling of days differed between years,
the model did not include a vaccine type by year interaction term,
thereby assuming differences between TIV and LAIV did not
depend on year (2004 vs. 2005). The primary comparison of
interest was the difference between TIV and LAIV in fitted means
between days 7 and 11 post-vaccination. Attained significance
levels of P,0.05 are considered to be statistically significant.
Adjustments for multiple comparisons were made as indicated,
via a sequential Bonferroni procedure [34]. Analyses were
conducted in Graph pad Prism v. 5.0 (GraphPad Software, Inc.,
San Diego, CA), SAS version 9.1 (SAS Institute, Cary, NC), and
S-Plus (Insightful Corp., Seattle, WA). All SAS and S-Plus code is
available upon request.
Results
Influence of TIV or LAIV vaccination in the prior year on
the serum antibody responses to new vaccination
To investigate the influence of prior year vaccination on the
serum antibody response to new vaccination, we compared the
HAI response between the three sub-groups of subjects who either
received TIV or LAIV influenza vaccines or were not vaccinated
in the prior year. We denote these prior year recipient groups of
TIV, LAIV or no vaccine as the 904-T, 904-L, and 904-N groups
with the following enrollments: 904-T group, n=19, 904-L group,
n=13, or 904-N group, n=28. We focused on HAI titer against
the H3N2 subtype virus because influenza A/H3N2 has, in recent
years, generally been a more virulent strain compared to the other
strains and has exhibited more antigenic variation from season to
season. H3N2 subtype viruses predominated in the USA during
the 2004–2005 influenza season and the strain has been drifting
over the past few years. Among these three treatment sub-groups,
we observed a significant difference in HAI titer against the H3N2
strain at baseline (day 0), prior to immunization in the current
study (Figure 1A). In agreement with previous studies by our group
and others [5,21,30], the 904-T group had a significantly higher
baseline HAI titer ([24: 14–42], geometric mean with 95%
confidence interval) compared to the 904-N group ([7: 5–11],
P=.001, unpaired t-test) and the 904-L group ([3: 2–5], P,.0001,
unpaired t-test with Welch’s correction). Although our previous
report showed that both TIV and LAIV induced increased serum
antibody titers one month after vaccination [5], a year later, the
904-L group had a significantly lower geometric mean HAI titer
compared to the 904-N group (P=.024, unpaired t-test).
One month after vaccination, both LAIV (905-LAIV) and TIV
(905-TIV) induced significant increases in geometric mean HAItiter
against H3N2 compared to baseline (P,.0001, Wilcoxon signed
rank test), and 905-TIV recipients reached significantly higher
geometric mean HAI titer compared to 905-LAIV recipients ([79:
55–114] vs. [28: 19–42], P=.0003, unpaired t-test). These data
suggest that the vaccines used in this study induced similar antibody
responses as described in previous studies [5].
After 905-LAIV vaccination, the mean fold-increase in HAI titer
in the 904-T group [2: 1–3] was smaller than either the 904-N
group or 904-L group ([4: 2–7] and [5: 1–19], P=.036 and .037,
respectively, unpaired t-test) (Figure 1B). This same tendency was
observed in 905-TIV recipients, in which there was a smaller fold-
increase of HAI titer in the 904-T group than the 904-L group
(P=.021, unpaired t-test) (Figure 1B). Taken together, these results
suggest that the status of prior year influenza vaccination
influences the influenza strain-specific antibody level a year after
vaccination as well as the changes in antibody titer after new
annual flu vaccination. Compared to subjects who were not
vaccinated, TIV vaccination in the prior year resulted in higher
baseline serum antibody, while LAIV vaccination resulted in lower
serum antibody titers one year later. One month after vaccination
with either 905-LAIV or 905-TIV, the fold-increase in HAI titers
was lower in the subjects who received TIV in the prior year than
in those who received LAIV previously.
Influence of TIV or LAIV immunization in the prior year on
the effector B-cell responses to new vaccination
Before vaccination (day 0), influenza-specific IgA and IgG ASC
were not detected in the circulation of most adults (only 3 out of 31
adults vaccinated in the prior year and only 2 out of 27 adults not
vaccinated had detectable ASC with one ASC/million PBMC, all
others were below the detection threshold). The frequency of
influenza-specific ASC in PBMC obtained 7–9 days after 905-
LAIV or 905-TIV vaccination was determined by direct ELI-
SPOT assay. In agreement with previous findings [5], the mean
number of effector IgA and IgG ASC per million PBMC was
significantly greater in 905-TIV recipients than in 905-LAIV
recipients (IgA ASC: [70: 37–130] vs. [11: 5–21], IgG ASC: [275:
160–472] vs. [29: 14–58], P=.0001 and ,.0001, respectively,
unpaired t-test) (Figure 2A). Next, we compared the effector B-cell
responses to 905-LAIV or 905-TIV in recipients who had received
LAIV, TIV or no vaccine in the prior year (Figure 2B). Significant
differences were not detected in the number of influenza-specific
IgA or IgG ASC among the three groups following 905-LAIV
vaccination (P$.161 for all comparisons, unpaired t-test). In
contrast, in 905-TIV recipients, the mean number of IgA ASC in
the 904-T group [14: 2–79] was lower than that in the 904-N group
[90: 36–220] or 904-L group [135: 57–315]. These differences are
statistically or marginally significant between the 904-T and 904-L
groups (P=.007, unpaired t-test) and the 904-T and 904-N groups
(P=.03, unpaired t-test) after adjustment for multiple comparisons
(Figure 2B). The effector IgG ASC response after 905-TIV in the
three groups followed a similar trend to the effector IgA ASC
B-Cell Response
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These data suggest that prior year vaccination with TIV, but not
LAIV, reduced the IgA effector B-cell response to new TIV
immunization and may have a similar effect on the IgG B-cell
response.
Kinetics of influenza-specific effector B-cell responses to
TIV and LAIV
The peripheral blood effector B-cell response after TIV
vaccination may be transient [35,36], while the kinetics of the
effector B-cell response after LAIV vaccination are unknown. To
compare the kinetics of effector B cells in the periphery after
vaccination with LAIV or TIV, we used the effector B-cell
ELISPOT data collected in 2004 [5] and 2005. On day 0 (before
vaccination), the number of IgG and IgA effector cells was under
the limit of detection in almost all subjects. Effector B cells were
detected during days 7–11 after vaccination, and largely
disappeared by days 21–36 in both TIV and LAIV recipients
(Figure 3). In agreement with previous reports [5], both IgG and
IgA ASC response declined from day 7 to day 11 after vaccination
with either TIV or LAIV. However, the average rate of decline
during this period, defined as the difference in the fitted regression
means between days 7 and 11, is significantly greater in the TIV
groups compared to the LAIV group (P=.0203 and .0036 for IgA
and IgG effector B cells, respectively). These results indicate that
the circulating effector B-cell response to TIV subsides faster than
that to LAIV.
Influence of prior TIV or LAIV vaccination status on the
memory B-cell responses to new vaccination
Previously we observed that most adults had preexisting
influenza-specific memory IgG B cells in their circulation before
Figure 1. HAI titer to influenza A/California (H3N2) strain before and 30 days after TIV or LAIV administration. Subjects are divided
into three groups based on the status of influenza vaccination in the prior year (2004–2005): TIV (’04-T), LAIV (’04-L), or no vaccination (’04-N). A:
Baseline HAI titer. B: fold-increase of HAI titer from baseline to day 30 of LAIV (’05-LAIV) or TIV (’05-TIV). The dashed-bars in each graph indicate the
geometric mean values. **, significant difference after sequential Bonferroni adjustment for multiple comparisons. *, results with a P value of ,.05 in
an individual unpaired t-test but nonsignificant after sequential Bonferroni adjustment for multiple comparisons.
doi:10.1371/journal.pone.0002975.g001
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immunization, the percentage of influenza-specific memory IgG B
cells in circulation increased significantly, with a higher percentage
of memory IgA and IgG B cells induced by TIV compared to
LAIV [5]. In the current study we again studied the memory B-cell
levels before and one month after 905-TIV and 905-LAIV
vaccination in adult subjects (Figure 4). Of the 61 adults, we
analyzed the memory B-cell response in the 37 adults who were
Figure 2. Frequency of circulating influenza-specific ASC after LAIV or TIV vaccination. Influenza-specific IgA ASC and IgG ASC were
measured with a direct ELISPOT assay at days 7–9 after LAIV (’05-LAIV) or TIV (’05-TIV) vaccination. A: Influenza-specific IgA and IgG ASC in all subjects
after administration of ’05-LAIV or ’05-TIV. B: Influenza-specific IgA and IgG ASC after ’05-LAIV or ’05-TIV in the three sub-groups based on influenza
vaccination status in the prior year: TIV (’04-T), LAIV (’04-L), or no vaccination (’04-N). The dashed-bars in each graph indicate the geometric mean
values. **, P,.01 unpaired t-test (A) or significant difference after adjustment for multiple comparisons (B). *, result with a P value of ,.05 in an
individual test but not significant after adjustment for multiple comparisons (B).
doi:10.1371/journal.pone.0002975.g002
B-Cell Response
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effector IgA and IgG ASC as a function of days after TIV or LAIV vaccination for the 2004 and 2005 studies. Observed data are plotted as circles and
triangles. Lines provide the fit of the GEE regression model. Of interest was comparing the difference in the slopes of these fitted lines over days 7–11
post-vaccination between TIV and LAIV. Regression analysis assumed that this difference between TIV and LAIV did not depend on year (2004 vs.
2005).
doi:10.1371/journal.pone.0002975.g003
B-Cell Response
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received TIV, one had received LAIV, and 28 had not received
either vaccine in the prior year. At baseline (day 0), no significant
difference was detected in the average percentages of circulating
influenza-specific memory IgA and IgG B cells between the 905-
LAIV and 905-TIV groups (P=.682 and .71, respectively,
unpaired t-test) (Figure 4A). One month after immunization,
significant increases in the percentage of influenza-specific
memory IgG B cells were observed in both 905-LAIV and 905-
TIV recipients, with the increase in 905-TIV recipients signifi-
cantly greater than that in the 905-LAIV recipients (2.5060.44,
mean6standard error vs. 0.7360.23, P=.0019, unpaired t-test
with Welch’s correction). The mean percentage of memory IgA B
cells also significantly increased in 905-TIV recipients (P=.039,
unpaired t-test with Welch’s correction), while no significant
increase was detected in the new 905-LAIV recipients.
To explore the influence of prior year vaccination on influenza-
specific memory B-cell responses, we used the day 0 and day 30
memory B-cell datasets derived from our previous study (2004
study) and the current study (2005 study). These included a 903-L
group and a 903-T group from the 2004 study, as well as a 904-N
group and a 904-T group from the 2005 study. A 904-L group
from the 2005 study was not available because only one subject in
this study received LAIV in the prior year. We observed a
significant increase in mean percentage of influenza-specific
memory IgG B cells one month after TIV vaccination in both
2005 and 2004 studies (Figure 4A and [5]), with 69% of the TIV
recipients experiencing an increase greater than three-fold.
However, in the 2005 study a significant difference was no longer
detectable in the baseline levels of memory IgG B cells between the
904-T group, which received TIV in the prior year, and the 904-N
group, which did not receive an influenza vaccine in the prior year
(P=.122, unpaired t-test, Figure 4B). Similarly, although 905-TIV
vaccination in the current study resulted in a greater mean
percentage of memory IgG B-cells one month after vaccination
than 905-LAIV (Figure 4A and [5]), in our 2004 study no
significant difference was detected in the baseline percentage of the
memory IgG B-cells between the 903-T and 903-L groups
(P=.089, unpaired t-test with Welch’s correction) (Figure 4B
and [5]). Taken together, these results suggest that regardless of
the status of prior year vaccination and the 30 day B-cell memory
response following vaccination, the percentage of circulating
influenza-specific memory B cells returned to statistically indistin-
guishable levels one year after vaccination in the adult vaccinees.
One month after either 905-LAIV or 905-TIV vaccination, no
significant difference was detected in the mean percentage of
influenza-specific memory B cells between the 904-N group and 904-
T group (Figure 4C). In addition, no significant difference was
detected in the mean change of percentage influenza-specific
memory B cells from baseline between the 904-N group and 904-T
group (data not shown). Taken together, these results suggest that
althoughTIVandLAIVinduced differentlevelsofinfluenza-specific
memory IgG B cells one month after vaccination, prior year
vaccinationstatusdoesnot affectmemoryIgGB-cellresponsesinthe
blood one month after vaccination with either TIV or LAIV.
Correlation between serum antibody and B-cell
responses after LAIV or TIV
Most adults have circulating antibodies against influenza viruses
due to prior exposure to influenza infection and/or vaccination.
To explore the effects of these antibodies on the immune responses
induced by a new vaccination, we analyzed the correlations
between baseline HAI titer and the following immune responses
after vaccination with either 905-TIV or 905-LAIV: serological
response, defined as the fold-change of HAI from day 0 (baseline)
to day 30; and memory B-cell responses, defined as the percentage
increase of influenza-specific IgG and IgA memory B cells from
day 0 to day 30. For effector B-cell responses, since influenza-
specific ASC were not detected at day 0 (Figure 3), we defined
effector B-cell response as the number of influenza-specific IgG
and IgA ASC per million PBMC at day 7–9. The results of these
analyses are summarized in Table 1. A significant inverse
correlation was observed between the fold-change of HAI titer
after vaccination and baseline HAI titer in both 905-LAIV and
905-TIV groups. In the 905-TIV group, an inverse correlation was
also observed between the effector B-cell response and baseline
HAI, especially HAI against the H1N1 strain. In the 905-LAIV
group, an inverse correlation was observed between the memory
IgA B-cell response and baseline HAI titer against H3N2, but no
correlation was observed between memory B-cell responses and
the baseline HAI titer in the rest of the combinations. In addition,
a significant positive correlation was observed between the serum
antibody response and effector B-cell response after vaccination,
especially after 905-LAIV, and between IgG memory B-cell
response and serum antibody response in the 905-TIV group
(Table 2).
Discussion
The goal of this study was to investigate the relationship
between prior immune status and B-cell immune responses to
influenza vaccination. Here we report that higher levels of
preexisting serum HAI antibodies are associated with reduced
serum antibody responses after vaccination with either LAIV or
TIV. Similar findings have been noted previously [6,21,37–40].
Moreover, higher levels of preexisting serum antibodies are
associated with a reduced peripheral effector B-cell response to
TIV but not LAIV. We also found that the serum antibody and
effector B-cell responses to vaccination were related to each other.
In addition to the similarities between TIV and LAIV, different
characteristics regarding their effects on B-cell immune responses
to subsequent immunization are also identified such as the kinetics
of effector B cells and the influence of preexisting antibodies on the
induction of effector B cells.
Influenza A/California, which was a new variant strain of A/
Fujian that was dissimilar to the vaccine strain A/Wyoming for the
2004–2005 season and was isolated in our local area, was the
dominant circulating H3N2 strain during the 2004–2005 season
[2,3]. The reported efficacy in adults of the influenza vaccines
against both circulating influenza A (A/California-like) and B
viruses in the 2004–2005 season was 77% for TIV and 57% for
LAIV [41]. Half the subjects recruited for the current study
conducted during the 2005–2006 season received either TIV or
LAIV in the prior year (2004–2005). We observed that subjects
who received TIV in the previous year (904-T group) had
significantly higher baseline HAI for H3N2 A/California
compared to those who received LAIV (904-L group) or no
vaccination (904-N group) in the prior year (Figure 1A). Although
the A/California used in the HAI assay is antigenically dissimilar
to A/Wyoming in the vaccine of the previous year, some
antibodies induced by A/Wyoming likely cross-react with A/
California [42] and contribute to the protection against the latter
[41]. This higher baseline HAI for A/California is likely to reflect
the long lasting antibody response induced by TIV in 2004.
Although LAIV induced a serum HAI response in the 2004–2005
season [5], the 904-L group had a lower baseline HAI titer against
A/California a year after the previous immunization, even when
compared to the 904-N group. A plausible explanation for the
B-Cell Response
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subjects in the 904-N group were exposed to the circulating
influenza in the 2004–2005 season and some of them were infected
and seroconverted, which resulted in higher antibody levels
compared to those in the 904-L group who were protected from
the infection because they received LAIV. In agreement with this
explanation, the baseline HAI titer for H1N1 A/New Caledonia,
which had not circulated dominantly for several years [2,3], was
comparable between the 904-N and 904-T groups (data not
shown).
In the 905-LAIV and 905-TIV groups, an inverse correlation
was observed between baseline antibody and fold-increase of HAI
antibody after vaccination (Table 1), suggesting that serum
antibody response to vaccination may be affected by the levels
of circulating antibodies at the time of vaccination, with a higher
baseline antibody level associated with lower immune responses.
These results support studies showing weaker serum responses
after LAIV in seropositive people compared to the seronegatives
[40,43]. Interestingly, baseline serum HAI antibody titer also
affected the peripheral effector B-cell response to 905-TIV, but not
905-LAIV which is consistent with prior studies demonstrating that
ASC responses are a more sensitive indicator than HAI of vaccine
‘‘take’’ following LAIV administration [5]. The route of
administration and type of vaccine can influence the induction
of effector B-cell response. Because TIV is injected intramuscu-
larly, some of the injected HA protein could be complexed by
preexisting antibodies in circulation, which may reduce the
amount of antigen available for stimulating naı ¨ve and/or memory
B-cells. Atmar et al. found a significant positive correlation
between dose of intramuscular administration of TIV and
antibody titer after vaccination [44]. In contrast, replication of
LAIV in the nasal mucosa is more directly related to mucosal
immunity, including local cellular and humoral mediators, than to
serum antibody [45]. Therefore, the magnitude of effector B-cell
responses after 905-LAIV may be less likely to be affected by
preexisting circulating antibodies. It will be interesting to
investigate the relationship between the B-cell responses and
other cellular immune responses to LAIV compared to TIV in
future studies.
In agreement with previous reports [35,36], after vaccination
with 905-TIV, effector B-cells transiently appeared in the
circulation with a sharp peak around day 7, and quickly
disappeared thereafter (Figure 3 and [5]). The temporal
appearance of circulating effector B-cells after LAIV immuniza-
tion has not been studied previously. In the current study we
observed a difference between LAIV and TIV in the kinetics of
effector B-cell appearance in the circulation during the period
from day 7 to 11 post-vaccination. The overall number of flu-
specific ASC was significantly higher in the 905-TIV recipients
than the 905-LAIV recipients (Figures 2 and 3), while the decline
of both IgG and IgA effector B-cells was significantly faster in TIV
recipients. The different kinetics are likely to reflect the
mechanism of induction of immunity by the two vaccines. After
an injection of TIV, naive or memory B-cells are exposed to a
synchronized administration of non-replicating antigen, start to
differentiate into effector B-cells, enter the circulation approxi-
mately 7 days later, and then traffic to the effector sites and
disappear from circulation quickly. Induction of effector B-cells
after intranasal delivery of LAIV is related to the asynchronous
replication of LAIV, which is subjected to inter-personal variation
in terms of actual dosing, antigen presentation and viral
replication. Collectively these factors are likely to result in less
synchronized B-cell responses among study subjects. Of note, our
assay was not designed to measure the ASCs specific for individual
Table 1. Correlation between baseline HAI titer and B-cell immune responses.
Group Immune responses (change from day 0) Baseline HAI
H3N2 H1N1
Spearman’s r P value Spearman’s r P value
LAIV HAI (day 30) 2.5442 .0023 2.3817 .041
Effector IgA (day 7) 2.2351 .2195 2.2886 .129
Effector IgG (day 7) 2.2469 .1966 2.3607 .0545
Memory IgA (day 30) 2.6746 .0015 2.2916 .2258
Memory IgG (day 30) 2.1453 .5529 2.2343 .3344
TIV HAI (day 30) 2.7225 ,.0001 2.803 ,.0001
Effector IgA (day 7) 2.3954 .0338 2.489 .0071
Effector IgG (day 7) 2.3076 .1045 2.3849 .0392
Memory IgA (day 30) .1 .723 2.08 .776
Memory IgG (day 30) 2.2462 .3764 2.4143 .1247
doi:10.1371/journal.pone.0002975.t001
Figure 4. The percentage of circulating influenza-specific memory B cells before and after LAIV or TIV vaccination. Percentages of
influenza-specific memory IgG B-cells and IgA B-cells before (day 0) and 30 day (21–35 days in 2005 study, 27–47 days in 2004 study) after LAIV or TIV
vaccination were measured. A: Comparisons of the percentages of influenza-specific memory IgA and IgG B-cells on day 0 and day 30 after LAIV (’05-
LAIV) or TIV (’05-TIV) vaccination. B: Comparisons of memory IgG B-cell levels before vaccination in sub-groups based on the influenza vaccine
received in the prior year: TIV (’03-T, ’04-T), LAIV (’03-L), or no vaccination (’04-N). C: Comparisons of memory IgG B-cell levels one month after
vaccination with ’05-LAIV or ’05-TIV between sub-groups ’04-N and ’04-T. The horizontal bars indicate the mean values. *, P,.05, **, P,.01, unpaired
t-test.
doi:10.1371/journal.pone.0002975.g004
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more immunogenic than H1N1 or B strains, and that TIV
vaccination induced stronger antibody responses to all three
strains while LAIV tended to induce weaker responses to H1N1
and B strains [5,41]. Therefore, it is possible that the effector B-
cells detected after TIV were specific for three different virus-
specific ASC while those detected after LAIV were dominantly
against H3N2. Further studies will be needed to examine the
effector B-cell response against individual virus strains after these
two types of vaccines.
The positive correlation between effector B-cell response and
serum response (fold-increase of HAI antibody) after vaccination
suggests that the serum response is associated with the effector B-
cell response in the circulation. Although the HAI assay could not
distinguish the subclass of antibody, IgG antibody is a generally
dominant subclass in the serum and is a major contributor to HA
inhibition. Serum IgG and local IgA levels are known to be
correlated with protection from influenza infection [12]. Therefore
the effector IgG ASC response could serve as a surrogate marker
for protection efficacy of influenza vaccination. Although LAIV
induces a higher mucosal antibody response than TIV [15,16], we
observed significantly higher numbers of effector IgA cells after
TIV vaccination compared to LAIV (Figure 2 and [5]). Further
analysis of the mucosal IgA response and its relationship to the
effector IgA B-cell response in blood may clarify the relationship of
circulating effector IgA B-cells to different types of vaccines. In
addition, analysis for the expression of homing markers on the
circulating effector B-cells and the expression of homing ligands at
the site of immunization could help clarify the mechanism of
induction of the local immune response after immunization with
different influenza vaccines.
We observed a correlation between the baseline HAI titer and
effector B-cell responses, but not between the baseline HAI levels
and memory B-cell responses after vaccination, with the exception
of an inverse correlation between HAI for H3N2 and memory IgA
B-cell response in 905-LAIV (Table 1). Therefore, the mechanisms
for induction of effector B-cells might differ from those of memory
B-cells, which were less influenced or not influenced by preexisting
antibodies. Of note, the memory IgA B-cell increase was not
statistically significant in 905-LAIV group, indeed 63% of adults
did not have increased memory IgA B-cell in 905-LAIV (Figure 4).
Interestingly, the adults whose memory IgA B-cell increased after
905-LAIV had lower HAI titers against H3N2 before vaccination
(6 out of 7 adults had HAI#4). The remaining adults whose
memory IgA B-cell did not increase in 905-LAIV had preexisting
HAI titer (HAI$8, data not shown). The current study
demonstrated an increase in memory B-cell response after both
905-LAIV and 905-TIV (Figure 4), while in our previous study of
2004 such an increase was not seen in LAIV recipients [5]. The
different results between the 2004 and 2005 studies may also
indicate an effect of prior year vaccination status on the immune
responses after recent influenza vaccination. Amanna et al. studied
antibody titer and memory B-cell numbers in the blood and found
that there was no significant correlation between peripheral
memory B-cell numbers and antibody levels for five of the eight
antigens tested [46]. Further analysis of single strain-specific
antibody and memory B-cell responses will be important for
understanding the relationship between influenza-specific anti-
body and memory B-cell responses to LAIV and TIV, and their
impact on protective immunity against influenza infection.
Based onour results,the effectorB-cellresponsemeasured around
day7 could beusedasa highlyeffective surrogate markerforvaccine
‘‘take’’ compared to the more traditional 30 day antibody response
rate after LAIV and TIV vaccination. Earlier and more sensitive
confirmation of vaccine ‘‘take’’ rates by surrogate markers would be
especially useful in the case of LAIV vaccination where traditional
serology assays seem to be very insensitive.
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